Robert Kramer - 22 Feb 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Signature
/s/ S. Scott Lieberman, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
22 Feb 2022
Net transactions value
-$194,047
Form type
4
Filing time
24 Feb 2022, 17:56:56 UTC
Previous filing
11 May 2021
Next filing
25 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +4,264 +2.6% $0.000000 167,317 22 Feb 2022 Direct F1
transaction EBS Common Stock Tax liability $194,047 -4,595 -2.7% $42.23 162,722 22 Feb 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 16,065 shares of common stock, which is in excess of the 11,801 shares previously reported on February 28, 2019.
F2 Represents shares of common stock withheld to pay taxes.